BioCryst BSAV BCX4430 highly effective agaist yellow fever in preclinical model BioCryst Pharmaceuticals announced proof-of-principle data demonstrating that BCX4430 is efficacious and well tolerated in a preclinical disease model for evaluating efficacy against yellow fever virus infection. BCX4430 is the lead compound in BioCryst's broad-spectrum antiviral, or BSAV, research program. The objective of BioCryst's BSAV program is to develop broad-spectrum parenteral and oral therapeutics for viruses that pose a threat to national health and security.
News For BCRX From The Last 14 Days
Check below for free stories on BCRX the last two weeks.